CRDL Stock Summary and Trading Ideas (Cardiol Therapeutics - Class A Common Shares | NASDAQ:CRDL)

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Cardiol Therapeutics - Class A Common Shares trades on the NASDAQ stock market under the symbol CRDL.

As of June 22, 2026, CRDL stock price was flat at $1.06 with 266,732 million shares trading.

CRDL has a beta of 1.03, meaning it tends to be more sensitive to market movements. CRDL has a correlation of 0.03 to the broad based SPY ETF.

CRDL has a market cap of $122.19 million. This is considered a Micro Cap stock.

In the last 3 years, CRDL traded as high as $3.12 and as low as $.66.

CRDL has underperformed the market in the last year with a price return of -19.7% while the SPY ETF gained +26.5%. CRDL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +7.4% and -7.8%, respectively, while the SPY returned +13.1% and -1.4%, respectively.

CRDL support price is $1.03 and resistance is $1.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRDL shares will trade within this expected range on the day.